Competitive androgen receptor antagonists are used to treat prostate cancer but, even in the presence of such drugs, overexpression of androgen receptors can drive cellular proliferation ...

The distinct mechanisms of action of 5-aRIs and a 1-AR antagonists on the respective static and dynamic components of BPH lend themselves to use as combination therapy. The efficacy and safety of ...

Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of ...

The introduction of novel agents targeting the AR signaling axis, including steroid synthesis inhibitors such as abiraterone and potent AR antagonists such as enzalutamide, have demonstrated striking ...